New Mycobacterium avium antifolate shows synergistic effect when used in combination with dihydropteroate synthase inhibitors by Suling, W. J. et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2005, p. 4801–4803 Vol. 49, No. 11
0066-4804/05/$08.000 doi:10.1128/AAC.49.11.4801–4803.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
New Mycobacterium avium Antifolate Shows Synergistic Effect when
Used in Combination with Dihydropteroate Synthase Inhibitors
W. J. Suling,1 L. E. Seitz,1 R. C. Reynolds,1 and W. W. Barrow2*
Southern Research Institution, Birmingham, Alabama,1 and Center for Veterinary Health Sciences,
Oklahoma State University, Stillwater, Oklahoma2
Received 20 May 2005/Returned for modification 13 July 2005/Accepted 29 August 2005
Mycobacterium avium complex (MAC) is resistant to trimethoprim, an inhibitor of bacterial dihydrofolate
reductase (DHFR). A previously identified selective inhibitor of MAC DHFR, SRI-8858, was shown to have
synergistic activity in combination with dapsone and sulfamethoxazole, two drugs that inhibit bacterial
dihydropteroate synthase.
Effective chemotherapy of patients coinfected with Myco-
bacterium avium complex (MAC) and human immunodefi-
ciency virus is difficult, primarily because MAC is resistant to a
variety of antimycobacterial agents. Although some success has
been achieved through the rational use of multiple-drug com-
bination therapy, the resistant nature of MAC emphasizes the
need for new drugs.
Previously, we identified a specific group of 2,4-diamino-5-
methyl-5-deazapteridines (DMDPs) that are active against
MAC. Demonstration of the antimycobacterial activity of
these new antifolates was initially aided by efforts of the Na-
tional Institutes of Health-sponsored Tuberculosis Antimicro-
bial Acquisition and Coordinating Facility. Continued efforts
have resulted in a specific group of DMDPs that have selective
activity for MAC dihydrofolate reductase (DHFR) but not
human DHFR, which makes them good candidates for further
development (7). This is significant because MAC is intrinsi-
cally resistant to trimethoprim, a commonly used drug that
targets prokaryotic DHFRs but not human DHFR. We have
shown that the 50% inhibitory concentration of trimethoprim
for the MAC DHFR is 4,100 nM, in comparison to the new
DMDPs, which have 50% inhibitory concentrations around 1.0
nM (7). DHFR is a key enzyme in the folate biosynthetic
pathway that catalyzes the reduction of dihydrofolate to tetra-
hydrofolate, derivatives of which function in single carbon
transfers at various oxidation states for the synthesis of pu-
rines, methionine, glycine, pantothenate, thymidylate, and N-
formylmethionyl-tRNA (3, 5). Inhibition of DHFR leads to a
depletion of tetrahydrofolate derivatives and results ultimately
in inhibition of DNA, RNA, and protein synthesis (3, 5).
Trimethoprim is generally used in combination with sulfa-
methoxazole (SMX) to treat infections caused by susceptible
organisms. Sulfa drugs such as SMX inhibit another enzyme in
the folate pathway, dihydropteroate synthase (DHPS). A dual
blockage in the pathway is believed to be responsible for a
synergistic increase in activity seen with the drug combination
(4).
The objective of the present study was to evaluate the activ-
ity of a new DMDP, SRI-8858 (Fig. 1), in combination with
SMX and dapsone, two known inhibitors of bacterial DHPS.
This will hopefully shed some light on the ability of these new
DMDP derivatives to act in combination with clinically accept-
able DHPS inhibitors and aid in the development of dual drug
therapy for MAC infections.
(This information was presented in part at the 44th Annual
Interscience Conference on Antimicrobial Agents and Chemo-
therapy, October and November 2004.)
SRI-8858 {6-[2,5-diethoxyphenylamino)methyl]-2,4-diamino-
5-methylpyrido[2,3-d]pyrimidine} is the hydrochloride salt
form of SRI-8686, a DMDP derivative whose synthesis has
been described previously (7). Sulfamethoxazole and dapsone
were purchased from Sigma. All drugs were dissolved in di-
methyl sulfoxide at 10.24 mg/ml and stored frozen at 80°C.
For assay, serial twofold dilutions were made in assay medium
(see below), with the final dimethyl sulfoxide concentration
being 1.3%.
The MAC strains used for these studies were NJ168 (serovar
1), NJ211 (serovar 4/6), and NJ3404 (serovar 4), kindly sup-
plied by L. Heifets, National Jewish Center for Immunology
and Respiratory Diseases, Denver, CO. These strains were
used previously by us to show selective activity against MAC of
the DMDP derivatives (7).
Antimicrobial activity was evaluated with a colorimetric
broth microdilution assay as reported previously (1, 6, 7) ex-
cept for the medium composition. Frozen broth cultures were
thawed, diluted in assay medium (Middlebrook 7H9 broth
supplemented with 0.2% glycerol, albumin-dextrose-catalase
enrichment, 0.1% Casamino Acids, 0.001 mg/ml pantothenate,
and 0.02 mg/ml adenine) to about 2  105 CFU/ml, and used
as the inoculum. Drug dilutions (0.05 ml/well) at twice the
desired concentration were added to appropriate wells fol-
lowed by 0.05 ml of inoculum. Viability controls and uninocu-
lated drug and medium controls were included with each assay.
The plates were incubated at 37°C for 6 days, at which time the
redox indicator alamarBlue (Trek Diagnostic Systems) was
added to each well as a mixture with Tween 80. Incubation was
continued for 18 to 22 h. The plates were read in an optical
microtiter plate reader programmed to subtract the absor-
bance at 600 nm from that at 570 nm to blank out turbidity and
absorbance due to oxidized dye. The MIC was reported as the
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lowest concentration of drug yielding a differential absorbance
of zero or less. For MAC NJ168, MAC NJ211, and MAC
NJ3404, the MICs of SRI-8858 were 1.0 to 2.0, 0.25, and 0.13
to 0.5 g/ml, respectively. For the same three MAC strains, the
MICs of SMX were 32, 32, and 64 g/ml, respectively, and
the MICs of dapsone were 64, 64, and 32 g/ml, respectively.
For combination studies, SRI-8858 was tested with either
SMX or dapsone using a checkerboard format and the broth
microdilution assay described above. Assays with MAC NJ168
were performed in duplicate. Results from each drug combi-
nation were interpreted according to an interaction index (2).
This was calculated as the fractional inhibitory concentration
(FIC), which is the ratio of the MIC of each drug in combina-
tion to the MIC of that drug when used alone. The activity of
the combination was considered synergistic if the sum of the
FICs for a combination was less than 0.5. A sum of about 1 is
additive, and a sum of 1 is indicative of antagonism. The
diagonal line on the isobologram represents an additive effect;
a point below this line represents synergism and a point above
this line represents antagonism. The results are presented in
Tables 1 to 4 and the accompanying isobolograms (Fig. 1).
As shown in Fig. 1, the combination of SRI-8868 with SMZ
or dapsone is synergistic for MAC NJ168. This synergism was
also observed with MAC NJ211 and NJ3404 (Tables 1 through
4). The FICs for the MAC strains, at all concentrations of
drugs, were 0.5 or below. Maximum synergism for NJ168 was
observed when SRI-8858 was at 0.063 g/ml and SMX was at
2.0 g/ml (Fig. 1). Maximum synergism for NJ211 was ob-
served when SRI-8858 and SMX were at 0.016 and 0.25
g/ml, respectively (Table 1). Maximum synergism for NJ3404
was observed when SRI-8858 was at 0.016 g/ml and SMX was
at 0.25 g/ml, respectively (Table 2).
With regard to SRI-8858 and dapsone, synergism was also
noted with this combination of drugs (Fig. 1B and Tables 3 and
FIG. 1. Isobolograms of SRI-8858–SMX (A) and SRI-8858–dap-
sone (B) combinations against MAC NJ168. The MICs of SRI-8858
are 1.0 g/ml in panel A and 2.0 g/ml in panel B. The MIC of SMX
is 32 g/ml (A), and the MIC of dapsone is 64 g/ml (B).






SMX FIC of SMX FIC sum
0.25 1 0 0 1
0.13 0.5 0.25 0.008 0.51
0.063 0.25 0.25 0.008 0.26
0.031 0.13 0.25 0.008 0.14
0.016 0.063 0.25 0.008 0.071
0.016 0.063 1.0 0.031 0.094
0.016 0.063 4 0.13 0.19
0.016 0.063 8 0.25 0.31
0 0 32 1 1
a Bold numbers are the MICs of the given drugs.









0.5 1 0 0 1
0.25 0.5 0.25 0.004 0.5
0.13 0.25 0.25 0.004 0.25
0.063 0.13 0.25 0.004 0.13
0.031 0.063 0.25 0.004 0.067
0.016 0.031 0.25 0.004 0.035
0.016 0.031 1 0.016 0.047
0.016 0.031 4 0.063 0.094
0.016 0.031 8 0.13 0.16
0.016 0.031 16 0.25 0.28
0 0 >64 1 1
a Numbers in bold are the MICs of the given drugs.









0.25 1 0 0 1
0.13 0.5 0.25 0.004 0.5
0.063 0.25 0.25 0.004 0.25
0.031 0.13 0.5 0.008 0.14
0.016 0.063 1 0.016 0.079
0.016 0.063 4 0.063 0.13
0.016 0.063 16 0.25 0.31
0 0 64 1 1
a Bold numbers are the MICs of the given drugs.
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4). The maximum synergism for NJ168 was obtained when
SRI-8858 was within the range of 0.25 and 0.13 g/ml and
dapsone was within the range of 4 and 8 g/ml (Fig. 1B).
Maximum synergism for NJ211 was obtained with SRI-8858 at
0.016 and dapsone at 1.0 g/ml (Table 3). For NJ3404, the
maximum synergism was noted when SRI-8858 was 0.016 and
dapsone was 0.5 g/ml (Table 4).
These results demonstrate the utility of using a sulfonamide
in combination with the new antifolate SRI-8858. In all three
MAC strains, a synergistic effect was observed with both SMX
and dapsone. For SRI-8858–SMX combinations, synergism
was observed in all of the 22 combinations tested. For SRI-
8858–dapsone combinations, synergism was observed with all
of the 17 combinations tested. We understand that in vitro
methods used to predict in vivo activity (e.g., the FIC method)
are not highly reliable without some knowledge of the phar-
macologic parameters of the drug. However, our results are
preliminary and of sufficient interest to warrant further study.
This research was funded through NIH/NIAID grant AI-41348
(principal investigator, W.W.B.).
We thank the NIH-sponsored Tuberculosis Antimicrobial Acquisi-
tion and Coordinating Facility (TAACF) for initial screening of SRI-
8858.
REFERENCES
1. Collins, L. A., and S. G. Franzblau. 1997. Microplate Alamar blue assay
versus BACTEC 460 system for high-throughput screening of compounds
against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob.
Agents Chemother. 41:1004–1009.
2. Elion, G. B., S. Singer, and G. H. Hitchings. 1954. Antagonists of nucleic acid
derivatives. VIII. Synergism in combinations of biochemically related antime-
tabolites. J. Biol. Chem. 208:477–488.
3. Hartman, P. G. 1993. Molecular aspects and mechanism of action of dihy-
drofolate reductase inhibitors. J. Chemother. 5:369–376.
4. Hitchings, G. H., Jr. 1989. Nobel lecture in physiology or medicine—1988.
Selective inhibitors of dihydrofolate reductase. In Vitro Cell. Dev. Biol. 25:
303–310.
5. MacKenzie, R. E. 1984. Biogenesis and interconversion of substituted tetra-
hydrofolates, p. 256–306. In R. L. Blakley and S. J. Benkovic (ed.), Folates and
pterins, vol. 1. John Wiley & Sons, New York, N.Y.
6. Suling, W. J., R. C. Reynolds, E. W. Barrow, L. N. Wilson, J. R. Piper, and
W. W. Barrow. 1998. Susceptibilities of Mycobacterium tuberculosis and My-
cobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors
of dihydrofolate reductase. J. Antimicrob. Chemother. 42:811–815.
7. Suling, W. J., L. E. Seitz, V. Pathak, L. Westbrook, E. W. Barrow, S. Zywno-
van-Ginkel, R. C. Reynolds, J. R. Piper, and W. W. Barrow. 2000. Antimyco-
bacterial activity of 2,4-diamino-5-deazapteridine derivatives and effects on
mycobacterial dihydrofolate reductase (DHFR). Antimicrob. Agents Che-
mother. 44:2784–2793.









0.13 1 0 0 1
0.063 0.5 0.25 0.008 0.5
0.031 0.25 0.25 0.008 0.26
0.016 0.13 0.5 0.016 0.15
0.016 0.13 2 0.063 0.19
0.016 0.13 8 0.25 0.38
0 0 32 1 1
a Bold numbers are MICs of the given drugs.
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